跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2010/091/000360
CTRI/2010/091/000360招募中3 期

AN INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ESTABLISH THERAPEUTIC EQUIVALENCE OF 1000 mg MESALAMINE RECTAL SUPPOSITORIES AND CANASA® RECTAL SUPPOSITORIES (1000 mg MESALAMINE, USP) IN THE TREATMENT OF MILD TO MODERATE ULCERATIVE PROCTITIS

Sandoz Inc0 个研究点目标入组 533 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
3 期
状态
招募中
发起方
Sandoz Inc
入组人数
533
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •1. Adults, male and female, 18 to 65 years of age
  • •2. Active, mild to moderate UP, with disease activity not to exceed 15 cm beyond the anal verge: the upper disease boundary will be confirmed by flexible sigmoidoscopy/colonoscopy performed within 14 days of the Baseline Visit
  • •3. Newly diagnosed or newly relapsed UP, where newly relapsed UP is defined as UP that has relapsed within less than and equal to 6 weeks prior to the Baseline Visit
  • •4. A Disease Activity Index (DAI) score greater than or equal to 4 and less than or equal to 10 at the Baseline Visit; the DAI must include a Physician's Global Assessment (PGA) sub-score of less than or equal to 2, a rectal bleeding sub-score of greater than or equal to 1 and a mucosal appearance sub-score of greater than or equal to 1
  • •5. Histological confirmation of UP with a Histological Disease Activity Score > or equal to 1 for the biopsy taken from the most severe area of disease during the flexible sigmoidoscopy/colonoscopy performed within 14 days of the Baseline Visit
  • •6. For female patients of child-bearing potential, a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit; all female patients will be considered of child-bearing potential unless they are post-menopausal for at least one year or have been surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)
  • •7. Female patients of childbearing potential must be practicing one of the following methods of birth control and must agree to continue with regimen throughout the study: hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of one full cycle (based on the patient's usual menstrual cycle period) before investigational product administration; total abstinence from sexual intercourse (since the last menses before investigational product administration); intrauterine device; double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream); Male patients must also agree to use acceptable methods of birth control with their female partners, and this may include use of a male condom plus spermicide.
  • •8. Ability to give written informed consent
  • •9. Ability and willingness to comply with study requirements, including dosing procedures, diary completion, and study visits

排除标准

  • •1. Known history of allergic reaction or clinically significant intolerance to aspirin or salicylate derivatives (including mesalamine) or non-active ingredients of the investigational product
  • •2. Onset of UP relapse >6 weeks prior to the Baseline Visit for patients experiencing a relapse of their UP (i.e., patients who are not newly diagnosed)
  • •3. Severe UP as defined by a DAI score of greater than or equal to 11 or a PGA sub-score of 3
  • •4. Histological Disease Activity Score > or equal to 1 for the biopsy taken from the normal tissue above the disease margin during the flexible sigmoidoscopy/colonoscopy performed within 14 days of the Baseline Visit
  • •5. UP with disease involvement greater than 15 cm beyond the anal verge as confirmed on flexible sigmoidoscopy/colonoscopy
  • •6. Prior unsuccessful treatment of active UP or active ulcerative colitis with rectally administered mesalamine preparations of any strength
  • •7. Any prior treatment of UP or ulcerative colitis with any oral 5-aminosalicylic acid product if used at >2 g/day, regardless of treatment outcome
  • •8. Use of local, rectally administered therapies for UP or ulcerative colitis (e.g., suppositories or enemas containing mesalamine, etc.) within 30 days of the Baseline Visit
  • •9. Use of any of the following medications:
  • •- Biological therapies (e.g., infliximab) within 90 days of the Baseline Visit
  • •- Immunosuppressive/immunomodulating (e.g., azathioprine) medications within 90 days of the Baseline Visit
  • •- Oral, intravenous, intramuscular, or rectally administered corticosteroids within 30 days of the Baseline Visit; the use of intranasal and/or inhaled corticosteroids is permitted
  • •- Oral 5-aminosalicylic acid products within 7 days of the Baseline Visit, if used at & less than or equal to 2 g/day
  • •- Oral, intravenous, or intramuscular antibiotics within 7 days of the Baseline Visit
  • •- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) within 7 days of the Baseline Visit; low-dose aspirin (less than or equal to 325 mg/day) taken for cardio-protective reasons is permitted
  • •- Antidiarrheals, antispasmodics, and iron therapy within 7 days of the Baseline Visit
  • •- Transdermal nicotine products within 7 days of the Baseline Visit
  • •10. A change in regimen (i.e., dosage or frequency of use) of permitted medications within 30 days of the Baseline Visit, or any plans to change the regimen during the course of this study
  • •11. Use or treatment with an investigational drug, therapy, or device within 30 days of the Baseline Visit
  • •12. A planned change in tobacco usage (e.g., smoking, oral tobacco) during the study
  • •13. Female patients who are pregnant, planning a pregnancy, or who are breastfeeding
  • •14. Diseases interfering with the DAI assessment, including but not limited to, hemorrhoids and anal fissures
  • •15. History of Crohn Disease, short bowel syndrome, or bowel surgery (except appendectomy), or active peptic ulcer
  • •16. A positive stool culture for enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, Vibrio, E. coli O157/H7), detection of Clostridium difficile toxin through immunoassay, or enteric parasites and their ova (including Giardia, Cr

研究者

发起方
Sandoz Inc

相似试验

未知
不适用
AN EXPLORATORY, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, PARALLEL ARM DOSE RANGING STUDY TO DETERMINE THE ANTITUSSIVE EFFECTS OF FPO1 LOZENGES IN SUBJECTS WITH COUGH DUE TO UPPER RESPIRATORY TRACT INFECTIO
PER-026-12CERECOR INC.,9
进行中（未招募）
1 期
Studio per verificare efficacia, sicurezza e tollerabilità di bepranemab (UCB0107) in pazienti con deterioramento cognitivo o Malattia di Alzheimer (AD) lieveAlzheimer's Disease
EUCTR2020-005829-88-ITCB Biopharma SR450
进行中（未招募）
1 期
A DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED, SEQUENTIAL GROUP, MULTIPLE DOSE STUDY OF THE EFFICACY OF THE CRF1-RECEPTOR ANTAGONIST R317573 ON CCK-4 INDUCED ANXIETY IN HEALTHY MALE SUBJECTS. - N/A
EUCTR2006-001475-38-NLJanssen Cliag Ltd. C/O Johnson & Johnson PRD
Unknown
不适用
To check the efficacy of Anti pollution products
CTRI/2020/02/023537ITC Limited ITC Life Sciences Technology Centre
进行中（未招募）
不适用
A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP DOSE-RANGE EXPLORATION STUDY OF SATIVEX IN RELIEVING PAIN IN PATIENTS WITH ADVANCED CANCER, WHO EXPERIENCE INADEQUATE ANALGESIA DURING OPTIMIZED CHRONIC OPIOID THERAPY. - NDPAIN IN PATIENTS WITH ADVANCED CANCER, WHO EXPERIENCE INADEQUATE ANALGESIA DURING OPTIMIZED CHRONIC OPIOID THERAPYMedDRA version: 9.1Level: LLTClassification code 10058019Term: Cancer pain
EUCTR2007-005225-30-ITGW PHARMA LTD336